Thyroid cytology September 2019 alison.marker@addenbrookes.nhs.uk - - PowerPoint PPT Presentation

thyroid cytology september 2019
SMART_READER_LITE
LIVE PREVIEW

Thyroid cytology September 2019 alison.marker@addenbrookes.nhs.uk - - PowerPoint PPT Presentation

Thyroid cytology September 2019 alison.marker@addenbrookes.nhs.uk FNAC in pre-operative evaluation of thyroid disease of :- solitary/dominant thyroid nodule clinically obvious malignancy diffuse goitre Solitary/dominant thyroid


slide-1
SLIDE 1

Thyroid cytology September 2019

alison.marker@addenbrookes.nhs.uk

slide-2
SLIDE 2

FNAC in pre-operative evaluation of thyroid disease of :-

  • solitary/dominant thyroid nodule
  • clinically obvious malignancy
  • diffuse goitre
slide-3
SLIDE 3

Solitary/dominant thyroid nodule

  • prevalence of thyroid nodules 4-8%
  • approx. 5% are malignant
  • clinical, biochemical and radiological

investigations have limitations

  • FNAC has higher accuracy in pre-op

evaluation of thyroid nodules

slide-4
SLIDE 4

Solitary/dominant Thyroid Nodule

Benign

  • cysts
  • multinodular goitre with hyperplastic

nodule

  • adenoma

Malignant

  • papillary, follicular or medullary carcinoma
  • lymphoma
slide-5
SLIDE 5

Diagnostic Accuracy of Thyroid FNA

  • Sensitivity between 65% and 98%
  • Specificity of 76-100%
  • False negative rate of 0-5%
  • False positive rate of 0-5.7%
  • Overall accuracy of 69-97%.

Ref: RCPath guidance on reporting of thyroid cytology specimens 2016

slide-6
SLIDE 6

Comparison of Diff-Quick and Papanicolau staining in thyroid smears

Identification of .. Quick Diff Method Papanicolau Method

colloid +++ + cellular borders ++ + intracytoplasmic granules in medullary carcinoma

+++

  • xyphilic cells

+++ + nuclear details +/++ +++ nuclear inclusions ++ +++ nuclear grooves + +++

slide-7
SLIDE 7

Thyroid FNA

Cell block preparation

  • cell blocks

– preparation

  • plasma/thrombin clot

– tissue fragments

  • architecture

– immunohistochemistry

slide-8
SLIDE 8

Thyroid FNA Thy 1 Thy 3 Thy 2 Thy 4 Thy 5 Follow up ? See below Core biopsy/Surgery Surgical resection/ chemotherapy /radiotherapy Repeat FNA or core biopsy

slide-9
SLIDE 9

RCPath 2016

  • Non diagnostic for cytological diagnosis

(Thy 1 or Thy 1c if cystic)

  • Non-neoplastic (Thy 2 or Thy 2c if cystic)
  • Neoplasm possible (Thy 3)

– atypia/non-diagnostic (Thy 3a) – suggesting follicular neoplasm (Thy 3f)

  • Suspicious of malignancy (Thy 4)
  • Malignant (Thy 5)
slide-10
SLIDE 10

Thyroid FNA Thy 3f Lobectomy +/- thyroidectomy Thy 3a Repeat FNA or lobectomy

slide-11
SLIDE 11

Risk of malignancy*

Diagnostic Category Risk of malignancy (%) Thy1/Thy1c (unsatisfactory) 0-10 Thy2/Thy2c (benign) 0-3 Thy 3a (follicular lesion of uncertain significance

  • r atypia of uncertain significance)

5-15 Thy 3f (follicular neoplasm or suspicious of follicular neoplasm) 15-30 Thy 4 (suspicious) 60-75 Thy 5 (malignant) 97-100

slide-12
SLIDE 12

Thyroid FNAC Interpretation

Important

  • cellularity
  • cell:colloid ratio

– colloid difficult to interpret in bloodstained material

Not important

  • detailed cell morphology (follicular lesions)

Limitations

  • adequacy of material
  • overlapping morphological features
slide-13
SLIDE 13

Thyroid FNAC Interpretation

  • Colloid
  • Cystic lesions
  • Follicular pattern
  • Papillary pattern
  • Oncocytic/Hürthle cells
  • Lymphocyte rich pattern
  • Spindle cell pattern
slide-14
SLIDE 14

Colloid-HG stain

slide-15
SLIDE 15

Colloid Pap stain

slide-16
SLIDE 16

Skeletal muscle

Pap stain HG stain

slide-17
SLIDE 17

Skeletal muscle

slide-18
SLIDE 18

Cystic lesions

slide-19
SLIDE 19

Cyst Appearances

  • Colloid rich and few or no epithelial cells
  • Little or no colloid & macrophages *
  • Haemorrhagic cyst **
  • */** RISK OF PAPILLARY CARCINOMA c. 4%
slide-20
SLIDE 20

Cystic papillary carcinoma

slide-21
SLIDE 21

Follicular lesions (Thy 3a and f)

  • verlapping smear patterns

Adenomatoid nodule Follicular neoplasm

Decreasing colloid Increasing cellularity Repetitive microfollicular arrangement Syncytia, nuclear crowding and overlapping Increasing nuclear size

slide-22
SLIDE 22

Neoplasm possible (Thy 3)

Thy 3:

  • Atypia

– cytological/nuclear or architectural

  • Other features raising possibility of

neoplasia

  • Subdivided into Thy 3a and Thy 3f

categories

slide-23
SLIDE 23

Neoplasm possible (Thy 3a)

  • Sparsely cellular sample, predominantly microfollicular
  • Architectural atypia

– Mixed micro- and macrofollicular pattern (approx. equal proportions) and/or little colloid

  • Cytological/nuclear atypia such that papillary thyroid

carcinoma cannot be confidently excluded

  • Compromised specimen

– XS blood or thickly spread containing some atypical cells

  • Atypical cyst lining cells
  • Predominance of lymphoid cells with very scanty

epithelium

slide-24
SLIDE 24

Follicular pattern THY3a

slide-25
SLIDE 25

Neoplasm possible (Thy 3f)

  • Sample suggests follicular neoplasm

– Cellular sample – Microfollicles predominate – High cell to colloid ratio

  • Includes

– Follicular variant PTC – Samples consisting exclusively/almost exclusively of oncocytic cells (>75% cell content)

slide-26
SLIDE 26

Follicular pattern Thy 3f

Clot preparation

slide-27
SLIDE 27

Follicular pattern: papillary carcinoma

slide-28
SLIDE 28

Follicular pattern Thy 3f

  • Follicular variant of papillary carcinoma

– cellular with clusters, syncitia and follicles – colloid balls – cytological features of papillary carcinoma – giant cells

slide-29
SLIDE 29

Follicular pattern

  • Parathyroid adenoma

– resembles follicular or oxyphilic adenoma of thyroid – cellular smears, high proportion of naked nuclei – nuclei uniform, small, round

slide-30
SLIDE 30

Papillary pattern

  • Papillary carcinoma

– inclusions and grooves – strongly associated with thyroid malignancy therefore histological confirmation mandatory

  • Multinodular goitre

– papillary hyperplasia – pale nuclei with powdery chromatin in hyperplasia

  • Follicular adenoma

– cohesive branching epithelial tissue fragments but lack anatomical edge

slide-31
SLIDE 31

Papillary carcinoma

slide-32
SLIDE 32

Papillary carcinoma

slide-33
SLIDE 33

Papillary pattern

Branching fragments in hyperplasia

slide-34
SLIDE 34

Papillary pattern

Occasional grooves in follicular carcinoma

slide-35
SLIDE 35

Papillary pattern

  • Psammoma bodies

Papillary carcinoma Hurthle cell adenoma

slide-36
SLIDE 36

Oncocytic/Hürthle cells

  • Related to increasing age
  • Multinodular goitre
  • Neoplasm

– Oxyphil/Hürthle cell adenoma/carcinoma or

  • xyphilic variant of papillary carcinoma
  • Hashimoto’s thyroiditis
  • Parathyroid hyperplasia or adenoma
slide-37
SLIDE 37

Hurthle cell neoplasm

slide-38
SLIDE 38

Hashimoto’s thyroiditis

Follicular pattern

slide-39
SLIDE 39

Lymphoid infiltrate

  • Thyroiditis
  • Graves’ disease
  • PTLD
  • Lymphoma

– Rare, almost always on background of Hashi’s – Originate from marginal zone of lymphoid follicles

slide-40
SLIDE 40

Spindle cell/ pleomorphic cell pattern

Medullary carcinoma Anaplastic carcinoma Angiosarcoma Metastatic carcinoma Primary squamous carcinoma Colloid cyst

slide-41
SLIDE 41

Spindle cell pattern- medullary carcinoma

slide-42
SLIDE 42

Spindle cell/pleomorphic cell pattern - anaplastic carcinoma

slide-43
SLIDE 43

Spindle cell and pleomorphic cell pattern - metastatic carcinoma

slide-44
SLIDE 44

Spindle cell and pleomorphic cell pattern

  • multinodular goitre
slide-45
SLIDE 45

Molecular analysis of cytology

  • Use of molecular markers to aid in

diagnosis and patient stratification for possible further treatment has grown significantly

  • Molecular markers, such as BRAF, RAS,

RET/PTC, and PAX8/PPARγ, should be considered in the management of patients with indeterminate FNA cytology

  • Not in routine use in UK
slide-46
SLIDE 46

Immunohistochemistry Thy 3 or 4 lesions

  • Thyroglobulin, TTF1 and CD56
  • Gal-3, HBME1, PAX 8 and CK19
  • markers associated with thyroid cancer
  • none are specific

– BRAF if papillary ca. suspected

Medullary carcinoma

– Calcitonin, CEA, TTF-1 and general neuroendocrine markers

Anaplastic (undifferentiated) carcinoma

– Cytokeratin; vimentin; EMA and CEA (focal positivity)

Lymphoma

– Flow cytometry, lymphoma panel

?Parathyroid lesion

– PTH, TTF-1

slide-47
SLIDE 47

Suggested Reading

  • RCPath

– Tissue pathways for endocrine pathology 2012

– RCPath guidance on reporting of cytology specimens 2016 – Dataset for thyroid cancer histopathology reports 2014 and NIFTP addendum 2016

  • British Thyroid Association Guidelines for the

Management of Thyroid Cancer 2014

  • WHO Tumours of Endocrine Organs 2017
  • TNM Classification of Malignant Tumours 8th

Edn

  • Rosai and Ackerman’s Surgical Pathology
slide-48
SLIDE 48

Sample Answer

Follicular lesion, Thy 3f Description:

  • Cellular sample containing sheets and groups of follicular

epithelial cells, many with a microfollicular architecture. Thick colloid is evident within some of the microfollicles. There are no nuclear features to suggest papillary thyroid carcinoma. Conclusion:

  • Follicular lesion with features favouring a follicular

neoplasm (Thy 3f) Comment:

  • Discussion at MDT meeting with the clinical and

radiological findings is warranted

slide-49
SLIDE 49

Sample Answer

Papillary thyroid carcinoma, Thy 5 Description

  • Cellular sample containing sheets and groups of cells some

with a papillary architecture. The cells have enlarged oval

  • verlapping nuclei showing irregularity of the nuclear

membrane, grooving and intranuclear inclusions. Chromatin is pale and powdery. Scanty thick colloid and multinucleate cells are also identified. Conclusion

  • Papillary thyroid carcinoma (Thy 5)

Comment

  • Discussion at MDT meeting with the clinical and

radiological findings is warranted